RS50521B - Derivati tiazola i njihova upotreba - Google Patents
Derivati tiazola i njihova upotrebaInfo
- Publication number
- RS50521B RS50521B RSP20070410A RS50521B RS 50521 B RS50521 B RS 50521B RS P20070410 A RSP20070410 A RS P20070410A RS 50521 B RS50521 B RS 50521B
- Authority
- RS
- Serbia
- Prior art keywords
- diseases
- thiazole derivatives
- neturodegenerative
- prophylaxis
- transplantation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Psychology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
Abstract
Derivat tiazola prema formuli (I), naznačen time stoje R1 ostatak prema formuli -NR5R6;R2, R3 i R5 su, nezavisno, odabrani iz grupe koja se sastoji od H, C1-C6 alkil, C2-C6 alkenil i C2-C6 alkinil grupe;R4 je odabran iz grupe koja se sastoji od H, C1C6 alkil, C2-C6 alkenil i C2-C6 alkinil grupe i NR8 R9, gde su R8 i R9 , nezavisno, odabrani iz grupe koja se sastoji od H, C1-C6 alkil, C2-C6 alkenil, C2-C6 alkinil, C1-C6 alkil alkoksi karbonil i C1-C6 alkil aciloksi grupe;R6 je odabran iz grupe koja se sastoji od C1-C6 alkil, C2-C6 alkenil, C2-C6 alkinil, C1-C6 alkil alkoksi, aril, heteroaril, C3-C8 cikloalkil, C3-C8 heterocikloalkil, C1-C6 alkil aril, C1-C6 alkil heteroaril, C1-C6 alkil C3-C8 cikloalkil, C1-C6 alkil C3-C8 heterocikloalkil, C1-C6 alkil acil, C1C6 alkil karboksi, C1C6 alkil amino, C1-C6 alkil aminokarbonil, C1-C6 alkil alkoksikarbonil i C1-C6 alkil acil amino grupe; ili R5 i R6, zajedno sa atomima ugljenika za koje su vezani, grade zasićeni ili aromatični prsten od 5 do 8 članova koji, opciono, sadrži jedan ili više heteroatoma odabranih iz grupe koja se sastoji od O, N i S; gde se aril odnosi na nezasićenu atomatičnu karbocikličnu grupu koja sadrži od 6 do 14 ugljenikovih atoma i gde se heteroaril odnosi na monocikličnu heteroaromatičnu ili bicikličnu ili tricikličnu heteroaromatičnu grupu sa fuzionisanim prstenom;X je odabran iz grupe koja se sastoji od S i O; kao i izomere ovih jedinjenja za upotrebu kao medikament. Prijava sadrži još 25 zavisnih patentnih zahteva.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04100083 | 2004-01-12 | ||
| PCT/EP2005/050102 WO2005068444A2 (en) | 2004-01-12 | 2005-01-11 | Thiazole derivatives and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS50521B true RS50521B (sr) | 2010-05-07 |
Family
ID=34778214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RSP20070410 RS50521B (sr) | 2004-01-12 | 2005-01-11 | Derivati tiazola i njihova upotreba |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8802861B2 (sr) |
| EP (1) | EP1709019B1 (sr) |
| JP (1) | JP5290524B2 (sr) |
| KR (1) | KR101260521B1 (sr) |
| CN (1) | CN1926121B (sr) |
| AT (1) | ATE369349T1 (sr) |
| AU (1) | AU2005205201B2 (sr) |
| BR (1) | BRPI0506749A (sr) |
| CA (1) | CA2551415C (sr) |
| CY (1) | CY1106921T1 (sr) |
| DE (1) | DE602005001931T2 (sr) |
| DK (1) | DK1709019T3 (sr) |
| EA (1) | EA012328B1 (sr) |
| ES (1) | ES2287896T3 (sr) |
| HK (1) | HK1103720A1 (sr) |
| HR (1) | HRP20070357T3 (sr) |
| IL (1) | IL176764A (sr) |
| NO (1) | NO20063606L (sr) |
| NZ (1) | NZ548197A (sr) |
| PL (1) | PL1709019T3 (sr) |
| PT (1) | PT1709019E (sr) |
| RS (1) | RS50521B (sr) |
| SI (1) | SI1709019T1 (sr) |
| UA (1) | UA83099C2 (sr) |
| WO (1) | WO2005068444A2 (sr) |
| ZA (1) | ZA200605624B (sr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
| BRPI0517253A (pt) * | 2004-10-28 | 2008-10-07 | Irm Llc | compostos e composições como moduladores de trajetória de ouriço |
| CN101304995B (zh) | 2005-05-24 | 2011-10-19 | 默克雪兰诺有限公司 | 噻唑衍生物及其应用 |
| EP1741709A1 (en) | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals |
| KR20080091369A (ko) | 2006-01-18 | 2008-10-10 | 암젠 인크 | 단백질 키나제 ｂ （ｐｋｂ） 억제제로서 티아졸 화합물 |
| NZ570103A (en) * | 2006-01-26 | 2011-11-25 | Foldrx Pharmaceuticals Inc | Compounds and methods for modulating protein trafficking |
| CN101657423B (zh) * | 2007-02-22 | 2013-11-06 | 先正达参股股份有限公司 | 亚胺吡啶衍生物和它们作为杀微生物剂的用途 |
| JP5616220B2 (ja) | 2007-06-01 | 2014-10-29 | ザ トラスティーズ オブ プリンストン ユニバーシティ | 宿主細胞代謝経路の調節によるウイルス感染治療 |
| JP2010533715A (ja) | 2007-07-17 | 2010-10-28 | アムジエン・インコーポレーテツド | 複素環系ｐｋｂ調節剤 |
| US7919504B2 (en) | 2007-07-17 | 2011-04-05 | Amgen Inc. | Thiadiazole modulators of PKB |
| WO2009051909A1 (en) * | 2007-10-16 | 2009-04-23 | The Regents Of The University Of California | Compounds having activity in correcting mutant-cftr cellular processing and uses thereof |
| AR069798A1 (es) | 2007-12-20 | 2010-02-17 | Novartis Ag | Derivados de 1, 3-tiazol, metodos para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la manufactura de medicamentos para el tratamiento de enfermedades mediadas por la fosfatidilinositol 3-cinasa. |
| EP2238134A2 (en) * | 2007-12-20 | 2010-10-13 | Novartis AG | Bis-thiazole derivatives, process for their preparation and their use as medicaments |
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
| JP2012531454A (ja) | 2009-07-02 | 2012-12-10 | ノバルティス アーゲー | Ｐｉ３ｋ阻害剤として有用な２−カルボキサミドシクロアミノウレア類 |
| JPWO2011048936A1 (ja) * | 2009-10-19 | 2013-03-07 | 大正製薬株式会社 | アミノチアゾール誘導体 |
| US20120129842A1 (en) | 2010-11-18 | 2012-05-24 | Paul Francis Jackson | Bisthiazole inhibitors of pro-matrix metalloproteinase activation |
| WO2012162468A1 (en) | 2011-05-25 | 2012-11-29 | Janssen Pharmaceutica Nv | Thiazol derivatives as pro -matrix metalloproteinase inhibitors |
| US8753857B2 (en) | 2011-06-29 | 2014-06-17 | Janssen Pharmaceutica N.V. | Crystal structure of the pro form of a matrix metalloproteinase and an allosteric processing inhibitor |
| US8798939B2 (en) | 2011-06-29 | 2014-08-05 | Janssen Pharmaceutica N.V. | Methods for designing, selecting and/or optimizing allosteric processing inhibitors for matrix metalloproteinases |
| EP2726073A1 (en) | 2011-06-29 | 2014-05-07 | Janssen Pharmaceutica, N.V. | Methods of treatment using allosteric processing inhibitors for matrix metalloproteinases |
| WO2015046193A1 (ja) * | 2013-09-25 | 2015-04-02 | 塩野義製薬株式会社 | Ｔｒｐｖ４阻害活性を有する芳香族複素環式アミン誘導体 |
| EP3052480B1 (en) * | 2013-09-30 | 2020-11-11 | The Texas A & M University System | Compositions associated with and methods of managing neutrophil movement |
| GB201705263D0 (en) * | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
| CN108570043A (zh) * | 2018-06-20 | 2018-09-25 | 王延娇 | 一种化合物及其作为选择性pi3k抑制剂在治疗肿瘤中的应用 |
| EP3811940B1 (en) * | 2019-10-22 | 2023-05-10 | Kemijski Institut | Substituted 4,5'-bithiazoles as inhibitors of the human dna topoisomerase ii |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4649146A (en) * | 1983-01-31 | 1987-03-10 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole derivatives and pharmaceutical composition comprising the same |
| SE9302332D0 (sv) | 1993-07-06 | 1993-07-06 | Ab Astra | New compounds |
| US6262096B1 (en) | 1997-11-12 | 2001-07-17 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| JPH11209284A (ja) | 1998-01-27 | 1999-08-03 | Sagami Chem Res Center | 骨形成促進剤 |
| GB9823871D0 (en) | 1998-10-30 | 1998-12-23 | Pharmacia & Upjohn Spa | 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents |
| UA71971C2 (en) | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
| DE60112272T2 (de) * | 2000-04-27 | 2006-05-24 | Astellas Pharma Inc. | Imidazopyridin-derivate |
| JP2002053566A (ja) * | 2000-08-11 | 2002-02-19 | Japan Tobacco Inc | チアゾール化合物及びその医薬用途 |
| ES2254611T3 (es) * | 2001-05-11 | 2006-06-16 | Pfizer Products Inc. | Derivados de tiazol. |
| PE20030968A1 (es) | 2002-02-28 | 2004-01-12 | Novartis Ag | Derivados de 5-feniltiazol como inhibidores de cinasas |
| BRPI0517253A (pt) * | 2004-10-28 | 2008-10-07 | Irm Llc | compostos e composições como moduladores de trajetória de ouriço |
-
2005
- 2005-01-11 ES ES05701490T patent/ES2287896T3/es active Active
- 2005-01-11 US US10/585,635 patent/US8802861B2/en not_active Expired - Fee Related
- 2005-01-11 PL PL05701490T patent/PL1709019T3/pl unknown
- 2005-01-11 WO PCT/EP2005/050102 patent/WO2005068444A2/en active Application Filing
- 2005-01-11 AT AT05701490T patent/ATE369349T1/de active
- 2005-01-11 EA EA200601242A patent/EA012328B1/ru not_active IP Right Cessation
- 2005-01-11 JP JP2006548315A patent/JP5290524B2/ja not_active Expired - Fee Related
- 2005-01-11 ZA ZA200605624A patent/ZA200605624B/en unknown
- 2005-01-11 AU AU2005205201A patent/AU2005205201B2/en not_active Ceased
- 2005-01-11 RS RSP20070410 patent/RS50521B/sr unknown
- 2005-01-11 DE DE200560001931 patent/DE602005001931T2/de active Active
- 2005-01-11 DK DK05701490T patent/DK1709019T3/da active
- 2005-01-11 SI SI200530042T patent/SI1709019T1/sl unknown
- 2005-01-11 CA CA 2551415 patent/CA2551415C/en not_active Expired - Fee Related
- 2005-01-11 BR BRPI0506749-9A patent/BRPI0506749A/pt not_active IP Right Cessation
- 2005-01-11 CN CN200580006639XA patent/CN1926121B/zh not_active Expired - Fee Related
- 2005-01-11 PT PT05701490T patent/PT1709019E/pt unknown
- 2005-01-11 EP EP20050701490 patent/EP1709019B1/en active Active
- 2005-01-11 NZ NZ548197A patent/NZ548197A/en not_active IP Right Cessation
- 2005-11-01 UA UAA200607633A patent/UA83099C2/ru unknown
-
2006
- 2006-07-10 IL IL176764A patent/IL176764A/en not_active IP Right Cessation
- 2006-07-28 KR KR1020067015376A patent/KR101260521B1/ko not_active IP Right Cessation
- 2006-08-09 NO NO20063606A patent/NO20063606L/no not_active Application Discontinuation
-
2007
- 2007-05-28 HK HK07105602A patent/HK1103720A1/xx not_active IP Right Cessation
- 2007-08-14 HR HR20070357T patent/HRP20070357T3/xx unknown
- 2007-10-08 CY CY071101296T patent/CY1106921T1/el unknown
-
2014
- 2014-02-07 US US14/175,751 patent/US9150561B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1103720A1 (en) | Thiazole derivatives and use thereof | |
| UA96735C2 (en) | Thiazole derivatives and use thereof | |
| UA93374C2 (en) | Thiazole derivatives and use thereof | |
| HK1106773A1 (en) | Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors | |
| UA100358C2 (xx) | Похідні піразину та їх застосування | |
| MX2009009031A (es) | Compuestos de quinoxalina y uso de los mismos. | |
| RS115904A (en) | Azolidinone-vinyl fused benzene derivatives | |
| TW200616968A (en) | Compound having basic substituent and application thereof | |
| GEP20084452B (en) | Sulfonamide derivatives for the treatment of diseases | |
| SE0302304D0 (sv) | Novel compounds | |
| ATE495186T1 (de) | Antibakterielle amid-makrozyklen iv | |
| DE502005007472D1 (de) | Desoxo-nonadepsipeptide | |
| ATE410443T1 (de) | Heterocyclyl-substituierte nonadepsipeptide | |
| ATE455789T1 (de) | Substituierte nonadepsipeptide | |
| UA88314C2 (en) | Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors | |
| SE0200119D0 (sv) | Novel compounds |